Abaloparatide Peptide CAS 247062-33-5 Ideal for Postmenopausal Osteoporosis and Fracture Risk Reduction Preparations

Abaloparatide More Info

Abaloparatide, identified by the Chemical Abstracts Service Registry Number 247062-33-5, is a synthetic peptide analog of human parathyroid hormone-related protein, specifically comprising the first thirty-four amino acids of the native sequence. Its molecular structure is a complex polypeptide chain with the precise amino acid sequence of Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-2-MeAla-Lys-Leu-His-Thr-Ala-NH₂, which reflects the intricate engineering required to produce a molecule with specific receptor binding properties. The compound is officially recognized by several nomenclature identifiers including the United States Adopted Name, the International Nonproprietary Name, and the brand name Tymlos under which it is commercially marketed, and it is assigned the Unique Ingredient Identifier AVK0I6HY2U for unambiguous identification in regulatory and pharmaceutical contexts.

The pharmacological mechanism of abaloparatide is centered on its selective activation of the parathyroid hormone type 1 receptor, which is expressed predominantly on osteoblasts and bone stromal cells. Upon subcutaneous administration, abaloparatide binds to this G protein-coupled receptor and preferentially stabilizes a specific conformation that favors the activation of the cyclic adenosine monophosphate signaling pathway, leading to enhanced osteoblast activity and increased bone formation. This molecular selectivity distinguishes it from other agents in its class, as it promotes the G protein-dependent signaling pathway while having a more limited effect on pathways that would stimulate bone resorption. The net result is a potent anabolic effect that increases trabecular and cortical bone mass, improves bone microarchitecture, and enhances bone mineral density through what is termed modeling-based bone formation, where new bone is created on previously quiescent surfaces without prior resorption.

The clinical efficacy of abaloparatide has been firmly established through rigorous investigation, most notably the pivotal phase three Abaloparatide Comparator Trial In Vertebral Endpoints study, which randomized over two thousand postmenopausal women with osteoporosis to receive either abaloparatide, placebo, or the comparator anabolic agent teriparatide over an eighteen-month treatment period. The results demonstrated that abaloparatide treatment resulted in a dramatic and highly significant reduction in the risk of new vertebral fractures, with an incidence of less than one percent compared to over four percent in the placebo group, representing an approximate eighty-six percent relative risk reduction. Significant reductions were also observed for nonvertebral fractures and clinical fractures, and the compound consistently produced substantial gains in bone mineral density at the lumbar spine, total hip, and femoral neck, with some skeletal sites showing superiority over teriparatide in terms of the magnitude of BMD increase.

The therapeutic application of abaloparatide is specifically indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture, and it has more recently been approved for increasing bone mineral density in men with osteoporosis at high fracture risk. The recommended dosing regimen is eighty micrograms administered once daily by subcutaneous injection, and patients are typically advised to ensure adequate calcium and vitamin D intake throughout the treatment course. A critical aspect of its clinical use is the mandated maximum treatment duration of eighteen months, which stems from preclinical toxicology studies in rats that demonstrated an increased incidence of osteosarcoma with longer-term exposure, although extensive human post-marketing surveillance has not identified a similar signal. Following completion of the eighteen-month anabolic course, guidelines uniformly recommend transitioning to an antiresorptive agent such as a bisphosphonate or denosumab to consolidate and maintain the skeletal gains achieved.

The adverse effect profile of abaloparatide is characterized by a range of generally transient tolerability issues and a favorable safety pattern relative to some alternatives. The most commonly reported adverse events include hypercalciuria, dizziness, nausea, headache, arthralgia, and palpitations, with a notable incidence of orthostatic hypotension that reflects the compound's vasodilatory properties. Importantly, abaloparatide is associated with a significantly lower frequency of hypercalcemia compared to teriparatide, which represents a meaningful clinical distinction. Serious adverse events are uncommon and occur at rates similar to placebo, and large real-world pharmacovigilance studies have identified additional but rare signals such as tinnitus, visual acuity reduction, and sensory disturbances that  clinical awareness. The compound is contraindicated in patients with severe renal impairment, pre-existing hypercalcemia, or metabolic bone diseases other than osteoporosis, and it should not be used in populations where the benefits do not clearly outweigh the theoretical risk of osteosarcoma, such as those with Paget's disease or prior radiation therapy involving the skeleton.